Influenza Medication Market Research Report and Forecast up to 2025 Influenza Medication Market - Global Industry Anal

Influenza Medication Market - Global Industry
Analysis, Size, Share, Growth, Trends, and
Forecast 2017 - 2025
Influenza, commonly known as “flu,” is a respiratory disorder caused by an
influenza virus. It is an infectious disorder which is of three types: type A, type B,
and type C. The common symptoms of the disorder are cough, cold, fever, and sore
throat, which can be mild or severe. The disease is spread easily from person to
person by sneezing, coughing, or touching surfaces, and is generally diagnosed on
the basis of symptoms. Seasonal outbreak of influenza primarily occurs in winter.
Most people generally recover fully, but severe complications such as pneumonia
can also develop. The treatment for influenza aims to prevent such complications
and to ease the symptoms until the infection is cured. Initiation of antiviral
treatment is recommended for hospitalized patients as early as possible. Annual
vaccination for influenza is the best way to prevent its infection, as vaccination can
be done well before the exposure to the influenza virus, and can provide immunity
throughout the season of influenza. The complications of influenza result in more
than 200,000 patients in the U.S. to be hospitalized every year.
View Report @ http://www.transparencymarketresearch.com/influenza-
medication-market.html
Rise in prevalence of influenza infections and government participation in
prevention and treatment of infectious diseases in developing countries are major
factors driving the growth of the influenza medication market. However, high cost of
antiviral medications is expected to restrain the global market during the forecast
period.
The global influenza medication market can be segmented on the basis of
therapeutics, distribution channel, and region. Based on the therapeutics, the global
influenza medication market is segmented into typical influenza medications
(antivirals), light influenza medications (antibiotics), and pneumonia influenza
medications. The typical influenza medications segment accounted for a high
market share of influenza medications in 2016, which is attributed to its
effectiveness. Antivirals include major three FDA approved drugs, which are
zanamivir, oseltamivir, and peramivir. According to CDC, antiviral medications are
approximately 70% to 90% effective in the prevention of influenza and are
considered to be useful adjuncts to influenza vaccination. Rise in prevalence of
influenza in developing countries and shift of population toward preventive health
care are expected to drive the market growth of the typical influenza medications
segment during the forecast period. However, the light influenza medications